Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

MDX2003

Other · developed by ModeX Therapeutics, An OPKO Health Company

Phase 1/2 Most advanced trial
OPK Developer
1 Registered trials

What is MDX2003?

MDX2003 is an agent given by intravenous infusion. It is studied in B-cell lymphomas, including diffuse large B-cell lymphoma, follicular lymphoma and Waldenström macroglobulinemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Drug type
Other
Therapy area
Oncology
Developer
ModeX Therapeutics, An OPKO Health Company (OPK)
FDA status
Investigational, not approved in the US. Most advanced trial: Phase 1/2

🧪 Clinical trials

TrialPhaseConditionStatusSponsor
NCT07249905 Phase 1/2 Lymphoma Recruiting OPK

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

DLBCL - Diffuse Large B Cell LymphomaFL LymphomaFollicular Lymphoma (FL)HGBCLLymphomaLymphoplasmacytic LymphomaPMBCLWaldenström Macroglobulinemia (WM)

More from ModeX Therapeutics, An OPKO Health Company

Sources

Updated Oct 25, 2026. Something wrong or missing? Report it on the OPK page.

Follow OPK, the company behind MDX2003

See OPK's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.

OPK catalysts and pipeline →
Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.